Drug
Bay2927088 Formulation A
Bay2927088 Formulation A: highest development phase Phase 1/2, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| BAY2927088_formulation A NCT05099172 | Phase 1/2 | Advanced Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Bay2927088 Formulation A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.